206258-26-6

Basic information

• Product Name: 4-[methyl-(4-methoxy-benzenesulfonyl)-amino]-8-bromo-quinoline-3-carboxylic acid
• CAS NO: 206258-26-6
• Molecular Weight: 451.298
• Mol File: 206258-26-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-[methyl-(4-methoxy-benzenesulfonyl)-amino]-8-bromo-quinoline-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[methyl-(4-methoxy-benzenesulfonyl)-amino]-8-bromo-quinoline-3-carboxylic acid(206258-26-6)
• EPA Substance Registry System: 4-[methyl-(4-methoxy-benzenesulfonyl)-amino]-8-bromo-quinoline-3-carboxylic acid(206258-26-6)

Safety Data

• Hazardous Substances Data: 206258-26-6(Hazardous Substances Data)

Upstream product

• 206258-97-1 ethyl 4-chloro-8-bromo-3-quinolinecarboxylate 
• 7010-86-8 N-methyl-4-methoxybenzenesulfonamide 
• 615-36-1 2-bromoaniline 
• 35975-57-6 ethyl-8-bromo-4-hydroxyquinolyl-3-carboxylic acid ethyl ester 

Relevant articles and documents

Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors

Potent and selective bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors were synthesized by a novel convergent route. Selectivity and efficacy versus MMPs and TACE could be controlled by appropriate substitution on the scaffolds and by variation of the P1′ group. Select compounds were found to be effective in in vivo models of arthritis.

ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS

Compounds of the formula are provided wherein P and Q are provided that when P is Q is and vice versa; which are useful in disease conditions mediated by TNF- alpha , such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors

This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-α converting enzyme (TACE, tumor necrosis factor-α converting enzyme) of formula: B wherein B is P and Q are provided that when P is Q is and vice versa; or a pharmaceutically acceptable salt thereof.